2015 Fiscal Year Final Research Report
RNAi for the treatment of refractory pulmonary diseases
| Project/Area Number |
25461189
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
GABAZZA ESTEBAN 三重大学, 医学系研究科, 教授 (00293770)
TAGUCHI OSAMU 三重大学, 保健管理センター, 教授 (90197244)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | siRNA / RNAi / TGF / 肺線維症 |
|---|
| Outline of Final Research Achievements |
The nucleic acid innovative drug development is expected as a new therapeutic method for the refractory disease.We make the original nucleic acid as Japan original and aim at the innovative drug development to respiratory disease with the administration of the trans-airway.As a result of designing a nucleic acid using a mouse disease model, and having tested it, control of the disease clinical condition was found to be possible by a trans-airway nucleic acid medication.These results suggest that intra-tracheal instillation of RNAi agents may be useful for the therapy of pulmonary diseases.
|
| Free Research Field |
呼吸器内科学
|
